Roche and Evotec Collaborate to Develop Biomarkers in Oncology

By LabMedica International staff writers
Posted on 05 Jul 2011

Evotec AG (Hamburg, Germany) and F. Hoffmann-La Roche Ltd. (Roche; Basel, Switzerland) announced that they would work to develop jointly novel protein-activity based biomarkers for Roche's oncology drugs under development. Evotec's PhosphoScout platform will be used to discover protein-phosphorylations that predict favorable dosage and efficacy of targeted cancer drugs in patients. Roche will conduct the clinical trials and assess the development of companion diagnostics for patient stratification.

"We are very pleased to collaborate with Evotec AG and benefit from the PhosphoScout technology to identify appropriate pharmacodynamics and patient stratification biomarkers," said Mike Burgess, global head of oncology, Roche Pharma Research and Exploratory Development. "These biomarkers are core to the development of targeted therapeutics for cancer therapy."

"Biomarker-based personalized healthcare has led to a paradigm shift in cancer therapy," said Dr. Werner Lanthaler, CEO of Evotec AG. "We are proud to partner Evotec's novel biomarker concept with Roche, the world leading personalized healthcare company, and its Pharma Research and Development Organization."

Related Links:
Roche
Evotec